title: Urinary 18,19-dihydroxycorticosterone and 18-hydroxy-19-norcorticosterone excretion in patients with primary and secondary aldosteronism.
abstract: 18,19-Dihydroxycorticosterone (18,19(OH)2-B) and 18-hydroxy-19-norcorticosterone (18-OH-19-nor-B) measurements were carried out on the urine of patients with primary aldosteronism (PA), essential hypertension (EHT), and liver cirrhosis with (LC, SA (+)) and without (LC, SA (-)) aldosteronism. The separation of these steroids was performed by extraction and high-performance liquid chromatography followed by radioimmunoassay (RIA) with specific antibodies prepared in our laboratory. 18,19(OH)2-B excretion was elevated in patients with PA (24 +/- 5.9 [+/- SE] micrograms/24 hr; n = 15) and LC, SA (+) (83 +/- 9.4 micrograms/24 hr; n = 8). Values in LC, SA (-) (3.1 +/- 1.2 micrograms/24 hr; n = 8) and in EHT (3.7 +/- 0.4 micrograms/24 hr; n = 42) were found to be similar to those in normal subjects (5.5 +/- 0.9 micrograms/24 hr; n = 30). The values of urinary 18-OH-19-nor-B in PA and LC, SA (+) were higher than in LC, SA (-) EHT and normal subjects (P less than 0.05). Values in the latter three groups, as compared with each other, did not show significant alterations. Nothing is known about the biologic relevance of 18,19(OH)2-B and very little about that of 18-OH-19-nor-B, but the latter steroid seems to potentiate experimental renal hypertension. One can speculate about possible roles of both steroids as precursors of other steroids, e.g., the biologically potent mineralocorticoid 19-noraldosterone. The data obtained suggest that it is not relevant to measure the urinary levels of either steroid in these clinical syndromes.
authors.affiliation: Department of Pharmacology, University of Heidelberg, Germany.
authors.forename: Y
authors.initials: Y
authors.lastname: Takeda
authors.forename: K
authors.initials: K
authors.lastname: Bige
authors.forename: T
authors.initials: T
authors.lastname: Iwuanyanwu
authors.forename: S
authors.initials: S
authors.lastname: Lewicka
authors.forename: P
authors.initials: P
authors.lastname: Vecsei
authors.forename: S
authors.initials: S
authors.lastname: Abdelhamid
authors.forename: M
authors.initials: M
authors.lastname: Harnik
mesh_terms: D015069:18-Hydroxycorticosterone / Q000031:analogs & derivatives* / Q000652:urine; D000328:Adult; D000368:Aged; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications / Q000652:urine*; D006973:Hypertension / Q000150:complications / Q000652:urine*; D008103:Liver Cirrhosis / Q000652:urine; D008875:Middle Aged
chemical_list: C051358:18-hydroxy-19-norcorticosterone; C051957:18,19-dihydroxycorticosterone; D015069:18-Hydroxycorticosterone